JP7773152B2 - 免疫療法の化合物および方法 - Google Patents

免疫療法の化合物および方法

Info

Publication number
JP7773152B2
JP7773152B2 JP2022517139A JP2022517139A JP7773152B2 JP 7773152 B2 JP7773152 B2 JP 7773152B2 JP 2022517139 A JP2022517139 A JP 2022517139A JP 2022517139 A JP2022517139 A JP 2022517139A JP 7773152 B2 JP7773152 B2 JP 7773152B2
Authority
JP
Japan
Prior art keywords
compound
seq
cells
cell
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022517139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548145A (ja
JP2022548145A5 (https=
Inventor
エー．バレラ ダニエル
エス．ミラー ジェフリー
フェリシス マーティン
シュローダー マーティン
Original Assignee
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ
ジーティー バイオファーマ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リージェンツ オブ ザ ユニバーシティ オブ ミネソタ, ジーティー バイオファーマ，インコーポレイティド filed Critical リージェンツ オブ ザ ユニバーシティ オブ ミネソタ
Publication of JP2022548145A publication Critical patent/JP2022548145A/ja
Publication of JP2022548145A5 publication Critical patent/JP2022548145A5/ja
Priority to JP2025182211A priority Critical patent/JP2026021424A/ja
Application granted granted Critical
Publication of JP7773152B2 publication Critical patent/JP7773152B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022517139A 2019-09-16 2020-09-15 免疫療法の化合物および方法 Active JP7773152B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025182211A JP2026021424A (ja) 2019-09-16 2025-10-29 免疫療法の化合物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962901198P 2019-09-16 2019-09-16
US62/901,198 2019-09-16
PCT/US2020/050851 WO2021055342A1 (en) 2019-09-16 2020-09-15 Immunotherapy compounds and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025182211A Division JP2026021424A (ja) 2019-09-16 2025-10-29 免疫療法の化合物および方法

Publications (3)

Publication Number Publication Date
JP2022548145A JP2022548145A (ja) 2022-11-16
JP2022548145A5 JP2022548145A5 (https=) 2023-09-21
JP7773152B2 true JP7773152B2 (ja) 2025-11-19

Family

ID=74883667

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022517139A Active JP7773152B2 (ja) 2019-09-16 2020-09-15 免疫療法の化合物および方法
JP2025182211A Pending JP2026021424A (ja) 2019-09-16 2025-10-29 免疫療法の化合物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025182211A Pending JP2026021424A (ja) 2019-09-16 2025-10-29 免疫療法の化合物および方法

Country Status (10)

Country Link
US (1) US20220324972A1 (https=)
EP (1) EP4031565A4 (https=)
JP (2) JP7773152B2 (https=)
KR (1) KR20220087441A (https=)
CN (1) CN115023435B (https=)
AU (1) AU2020350524A1 (https=)
BR (1) BR112022004712A2 (https=)
CA (1) CA3154158A1 (https=)
IL (1) IL291343A (https=)
WO (1) WO2021055342A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200291130A1 (en) * 2017-03-31 2020-09-17 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
KR20240067088A (ko) * 2021-09-16 2024-05-16 지티 바이오파마, 인크. 융합 단백질을 표적으로 하는 pd-l1 및 이의 사용 방법
WO2025136820A1 (en) * 2023-12-18 2025-06-26 Regents Of The University Of Minnesota Poly-antigen cytokine-receptor complexes (paccs), compositions, and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018524373A (ja) 2015-07-15 2018-08-30 ザイムワークス，インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
JP2018531939A (ja) 2015-10-06 2018-11-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 治療用化合物及び方法
JP2019512272A (ja) 2016-03-21 2019-05-16 エルスター セラピューティクス， インコーポレイテッド 多重特異性および多機能性分子ならびにその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN01299A (https=) * 2012-07-23 2015-07-03 Zymeworks Inc
CA2924398A1 (en) * 2013-11-05 2015-05-14 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
KR102762243B1 (ko) * 2014-06-30 2025-02-05 알토 바이오사이언스 엘엘씨 Il-15-베이즈드 분자 및 이의 사용 방법
WO2019035938A1 (en) * 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018524373A (ja) 2015-07-15 2018-08-30 ザイムワークス，インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
JP2018531939A (ja) 2015-10-06 2018-11-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 治療用化合物及び方法
JP2019512272A (ja) 2016-03-21 2019-05-16 エルスター セラピューティクス， インコーポレイテッド 多重特異性および多機能性分子ならびにその使用

Also Published As

Publication number Publication date
BR112022004712A2 (pt) 2022-06-14
JP2022548145A (ja) 2022-11-16
KR20220087441A (ko) 2022-06-24
CN115023435A (zh) 2022-09-06
CA3154158A1 (en) 2021-03-25
AU2020350524A1 (en) 2022-04-21
WO2021055342A1 (en) 2021-03-25
EP4031565A1 (en) 2022-07-27
CN115023435B (zh) 2026-03-27
EP4031565A4 (en) 2023-10-25
US20220324972A1 (en) 2022-10-13
IL291343A (en) 2022-05-01
JP2026021424A (ja) 2026-02-10

Similar Documents

Publication Publication Date Title
US20240199736A1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP6875295B2 (ja) Ｔｉｇｉｔ結合物質およびその使用法
EP3423495B1 (en) Antibodies specific to human poliovirus receptor (pvr)
AU2015338974B2 (en) Combination therapy for treatment of disease
JP2026021424A (ja) 免疫療法の化合物および方法
US20170137533A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
EP4074732A1 (en) Fully human antibodies against ox40, method for preparing the same, and use thereof
CN108650886A (zh) 多价和多特异性gitr-结合融合蛋白
US12371493B2 (en) Monoclonal antibody against human LAG-3, method for preparing the same, and use thereof
AU2018221557C1 (en) Dosing schedule of a Wnt inhibitor and an anti-PD-1 antibody molecule in combination
JP2025527535A (ja) 抗ｃｃｒ８抗体およびその使用
JP2022514832A (ja) 抗ｔｉｍ－３抗体とその利用
WO2025232879A1 (en) Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
RU2812481C2 (ru) Вовлекающие nk молекулы и способы их применения
RU2808632C2 (ru) Виды комбинированной терапии рака, нацеливающиеся на cd38 и tgf-бета
TW202541837A (zh) 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
TW202540162A (zh) 含有結合至cldn18.2和cd3之雙特異性結合劑和抗vegfr2抗體之組合療法
TW202523694A (zh) 抗muc16抗體及其用途
HK40082317A (en) Fully human antibodies against ox40, method for preparing the same, and use thereof
AU2024380169A1 (en) Anti-muc16 antibodies and uses thereof
HK40079353A (en) Antibodies specific to human poliovirus receptor (pvr)
HK40001896B (en) Antibodies specific to human poliovirus receptor (pvr)
HK40001896A (en) Antibodies specific to human poliovirus receptor (pvr)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250905

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251029

R150 Certificate of patent or registration of utility model

Ref document number: 7773152

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150